Abstract

We classified clinical phenotypes based on tumor separability from the rectosigmoid colon and then evaluated the effect of these clinical phenotypes on surgical outcomes and prognosis of advanced ovarian cancer. We collected data of patients with stage IIIB-IVB disease who either underwent visceral segmental serosectomy (VSS) or low anterior resection (LAR) during maximal debulking surgery. All patients were divided into the following, according to the resection types of tumors involving the rectosigmoid colon: the focal (tumor-involved length <18 cm) and separable (FS) group that received VSS, the focal and inseparable (FI) that received LAR, or the diffuse (tumor-involved length ≥18 cm) group (D) that also received LAR. A total of 83 patients were included in FS (n=44, 53%), FI (n=18, 21.7%), and D (n=24, 25.3%) groups. FS and D groups with more extensive tumors were related to wider extent of surgery and more tumor infiltration except for bowels, whereas FI and D groups with more invasive tumors were associated with wider extent of surgery, more tumor infiltration to bowels, longer operation time, more blood loss, more transfusion, longer hospitalization, and higher surgical complexity scores. Moreover, FS and FI groups showed better progression-free survival than D group, whereas FS group demonstrated better overall survival than FI and D groups. Clinical phenotypes based on tumor separability from the rectosigmoid colon may depend on tumor invasiveness and extensiveness in advanced ovarian cancer. Moreover, these clinical phenotypes may affect surgical outcomes and survival.

Highlights

  • Maximal cytoreduction in advanced ovarian cancer is crucial [1, 2], removing tumors involving the rectosigmoid colon is burdensome for gynecologic oncologists during debulking surgery for advanced ovarian cancer

  • 44 (53%), 18 (21.7%), and 24 (25.3%) patients were assigned to focal and separable (FS), focal and inseparable (FI), and D groups, respectively

  • There were no differences in age, Federation of Obstetrics and Gynecology (FIGO) stage, histology, treatment types, use of bevacizumab, and followup duration among the three groups (Table 1)

Read more

Summary

Introduction

Maximal cytoreduction in advanced ovarian cancer is crucial [1, 2], removing tumors involving the rectosigmoid colon is burdensome for gynecologic oncologists during debulking surgery for advanced ovarian cancer. A few gynecologic oncologists themselves perform the removal of the tumor located in the rectosigmoid colon in clinical practice, while others commonly rely on colorectal surgeons in 80-90% of cases [3]. For removing tumors involving the rectosigmoid colon, low anterior resection (LAR) is a popular method with no risk of leaving microscopic residual tumor. It has been reported that 40% of patients who underwent LAR develop the low anterior resection syndrome, deteriorating quality of life [13, 14]

Objectives
Methods
Results
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call